A317450 logo

Myung In Pharmaceutical LTD. Stock Price

KOSE:A317450 Community·₩766.5b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A317450 Share Price Performance

₩0
-121900.00 (-100.00%)
₩0
-121900.00 (-100.00%)
Price ₩0

A317450 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with solid track record.

1 Risk
2 Rewards

Myung In Pharmaceutical LTD. Key Details

₩287.3b

Revenue

₩113.3b

Cost of Revenue

₩174.0b

Gross Profit

₩92.6b

Other Expenses

₩81.4b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
5.58k
60.57%
28.35%
0%
View Full Analysis

About A317450

Founded
1985
Employees
n/a
CEO
Hang-Myung Lee
WebsiteView website
myunginph.co.kr

Myung In Pharmaceutical LTD., a pharmaceutical company, manufactures ETC and OTC drugs. It offers products in the areas of thrombosis and anti-platelet, anti-hypertensive, anti-angina, anti-parkinson, anti-dementia, anti-epileptics, anti-schizophrenia, anti-depressants, adhd, anti-insomnia, gum disease treatment, gastrointestinal, cold-cough medicine, anti-fever, anti-pain, anti-inflammation agent, nutrition supplements and other pharmaceuticals. The company also provides APIs, such as benztropine mesylate, benidipine hcl, clopidogrel bisulfate, haloperidol, paroxetine hcl, pimozide, quetiapine fumarate, rasagiline mesylate, risperidone, sumatriptan succinate, trazodone hci, triazolam, levetiracetam, carbamazepine, benserazide hydrochloride, escitalopram oxalate, vortioxetine hbr, brivaracetam, edoxban tosylate, opicapone, brexpiprazole, guanfacine hydrochloride, lacosamide, lurasidone hydrochloride. Myung In Pharmaceutical LTD. was founded in 1985 and is based in Hwaseong-si, South Korea.

Recent A317450 News & Updates

Recent updates

No updates